Advances in therapy for soft-tissue sarcomas are difficult. Sarcomas are rare, accounting for less than 2% of all cancers. Large studies are difficult to conduct in small patient populations, and small but meaningful improvements cannot be shown in small studies. The diversity in this small group — there are approximately…
The New England Journal of Medicine: Search Results in Hematology/Oncology
